Provided by Tiger Trade Technology Pte. Ltd.

IDEAYA Biosciences

33.18
-0.5500-1.63%
Volume:541.44K
Turnover:18.25M
Market Cap:2.91B
PE:-18.20
High:34.33
Open:33.87
Low:33.11
Close:33.73
52wk High:37.08
52wk Low:13.45
Shares:87.67M
Float Shares:81.82M
Volume Ratio:0.74
T/O Rate:0.66%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.8227
EPS(LYR):-3.3605
ROE:-14.15%
ROA:-10.77%
PB:2.66
PE(LYR):-9.87

Loading ...

IDEAYA Biosciences Inc - to Begin Enrolling Study in Q1 2026

THOMSON REUTERS
·
Dec 01

IDEAYA Biosciences Announces Ind Clearance for Ide034, a Potential First-in-Class Bispecific B7h3/Ptk7 Top1 ADC Targeting Multiple Solid Tumor Types

THOMSON REUTERS
·
Dec 01

IDEAYA Biosciences Grants Stock Options to New Employee Under 2023 Inducement Plan

Reuters
·
Nov 28

IDEAYA Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
Nov 28

Assessing IDEAYA Biosciences (IDYA) Valuation Following Recent Share Price Momentum

Simply Wall St.
·
Nov 28

IDEAYA Biosciences Initiated at Buy by Truist Securities

Dow Jones
·
Nov 25

IDEAYA Biosciences CEO to Join Fireside Chats at Major Healthcare Investor Conferences

Reuters
·
Nov 24

Mizuho Raises Price Target on IDEAYA Biosciences to $46 From $44, Keeps Outperform Rating

MT Newswires Live
·
Nov 10

IDEAYA Biosciences (IDYA) Is Down 5.1% After Return to Profitability and Strong Q3 Earnings - Has The Bull Case Changed?

Simply Wall St.
·
Nov 09

IDEAYA Biosciences: Strong Buy Rating Backed by Promising Pipeline and Robust Financial Position

TIPRANKS
·
Nov 05

IDEAYA Biosciences Reports Strong Q3 2025 Results

TIPRANKS
·
Nov 05

IDEAYA Biosciences: Promising Clinical Developments and Strategic Potential Drive Buy Rating

TIPRANKS
·
Nov 04

IDEAYA Biosciences Q3 net income beats estimates

Reuters
·
Nov 04

IDEAYA Biosciences reports Q3 cash and securities of $1.14 billion

Reuters
·
Nov 04

IDEAYA Biosciences Inc - Has ~$1.14 Bln in Cash, Cash Equivalents, & Marketable Securities as of Sept 30; Expected to Fund Operations Into 2030

THOMSON REUTERS
·
Nov 04

IDEAYA Biosciences Q3 Collaboration Revenue USD 207.834 Million

THOMSON REUTERS
·
Nov 04

IDEAYA Biosciences Grants Stock Options to New Employees Under Inducement Plan

Reuters
·
Oct 31

IDEAYA Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
Oct 31

Press Release: IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Dow Jones
·
Oct 31

UBS Sticks to Their Buy Rating for IDEAYA Biosciences (IDYA)

TIPRANKS
·
Oct 25